Starton Therapeutics
Andy Rensink is an Executive bringing more than 30 years of operational experience including 13 years in transdermal development and manufacturing.
Mr. Rensink is the former President and COO of Tapemark, where he led development, strategy implementation for pharmaceutical CDMO developing and manufacturing Transdermal Patches and Oral Thin Film products. Currently, he sits on the Board of Advisors for Hydra-Flex chemical dispensing systems. He holds a Masters in Engineering from Marquette University, BSME from the University of Wisconsin, and completed the GE Manufacturing Management Program.
This person is not in any offices
Starton Therapeutics
Starton Therapeutics is a clinical-stage biotechnology company that is transforming standard-of-care therapies with proprietary transdermal technology, so people with cancer can receive continuous treatment to live better, longer.